de Braud, Filippo

Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches by Daniela Femia( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature by Arpine Gevorgyan( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer A pilot study by Barbara Jereczek-Fossa( )

1 edition published in 1998 in English and held by 2 WorldCat member libraries worldwide

Treatment of lung large cell neuroendocrine carcinoma by Giuseppe Lo Russo( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

<>( )

2 editions published in 2015 in English and held by 2 WorldCat member libraries worldwide

Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors( )

2 editions published between 2014 and 2015 in English and held by 2 WorldCat member libraries worldwide

Abstract : Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data in a real-world setting outside regulatory trials are sparse. The aim of this study was to determine everolimus tolerability and efficacy, in relation to previous treatments, in a compassionate use program. A total of 169 patients with advanced progressive NETs treated with everolimus were enrolled, including 85 with pancreatic NETs (pNETs) and 84 with nonpancreatic NETs (non-pNETs). Previous treatments included somatostatin analogs (92.9%), peptide receptor radionuclide therapy (PRRT; 50.3%), chemotherapy (49.7%), and PRRT and chemotherapy (22.8%). Overall, 85.2% of patients experienced adverse events (AEs), which were severe (grade 3-4) in 46.1%. The most frequent severe AEs were pneumonitis (8.3%), thrombocytopenia (7.7%), anemia (5.3%), and renal failure (3.5%). In patients previously treated with PRRT and chemotherapy, a 12-fold increased risk for severe toxicity was observed, with grade 3-4 AEs reported in 86.8% (vs. 34.3% in other patients). In addition, 63.3% of patients required temporarily everolimus discontinuation due to toxicity. Overall, 27.8% of patients died during a median follow-up of 12 months. Median progression-free survival (PFS) and overall survival (OS) were 12 months and 32 months, respectively. Similar disease control rates, PFS, and OS were reported in pNETs and non-pNETs. In the real-world setting, everolimus is safe and effective for the treatment of NETs of different origins. Higher severe toxicity occurred in patients previously treated with systemic chemotherapy and PRRT. This finding prompts caution when using this drug in pretreated patients and raises the issue of planning for everolimus before PRRT and chemotherapy in the therapeutic algorithm for advanced NETs. Abstract : The aim of this study was to determine everolimus tolerability and efficacy, in relation to previous treatments, in a compassionate use program for neuroendocrine tumors (NETs). Results showed that everolimus is safe and effective for the treatment of NETs of different origins. Higher severe toxicity occurred in patients previously treated with systemic chemotherapy and peptide receptor radionuclide therapy

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors by Giuseppe Lo Russo( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer by Claudio Vernieri( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections by Giuseppe Pelosi( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment by Ada Koschorke( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide